<DOC>
	<DOCNO>NCT00006471</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness fenretinide treat patient recurrent metastatic head neck cancer .</brief_summary>
	<brief_title>Fenretinide Treating Patients With Recurrent Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , time progression , median survival , percent 1-year survival patient recurrent metastatic squamous cell carcinoma head neck treat fenretinide . - Determine pharmacokinetics safety drug patient . OUTLINE : Patients receive oral fenretinide every 12 hour day 1-7 . Treatment repeat every 3 week least 3 course absence disease progression unacceptable toxicity . Patients achieve complete response continue treatment 1 year . PROJECTED ACCRUAL : A total 16-35 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>1 . Biopsyproven recurrent squamous cell carcinoma head neck 2 . Stage 4 disease , either initial presentation recurrence . Patients metastatic disease initial presentation must receive least one prior course cytotoxic chemotherapy . 3 . Patients present metastatic disease receive one prior regimen chemotherapy biologic therapy eligible . Patients initially receive adjuvant induction chemotherapy recur may receive one additional cycle chemotherapy biologic therapy time recurrence . Patients may receive number cycle particular regimen chemotherapy . 4 . Patients must life expectancy least 3 month 5 . Biopsy recurrent lesion ( ) encourage mandatory enrollment . 6 . Performance status grade 02 . 7 . Serum creatinine &lt; = 1.5 mg/dL . 8 . Serum transaminases bilirubin &lt; = 1.5 time normal . 9 . Age &gt; = 18 year . 10 . White blood cell count &gt; = 3,000 ; platelet &gt; = 100,000 ; hemoglobin &gt; = 9mg/dl . 11 . Signed informed consent . 12 . Women childbearing potential must agree utilize two method effective birth control , one barrier , one hormonal , abstain sexual intercourse could result pregnancy . Contraceptive measure continue least one month fenretinide administration discontinue . 13 . It recommend male patient female partner childbearing potential use barrier contraception fenretinide . 1 . Pregnant woman ( woman childbearing potential must negative pregnancy test within 24 hour prior enrollment study ) ; woman currently breastfeed . 2 . Grade 2 great peripheral neuropathy 3 . Concurrent treatment cytotoxic chemotherapy radiation 4 . Serious infection intercurrent illness require immediate therapy . 5 . Inability take oral medication , medical social factor interfere compliance . 6 . Patients high dose synthetic natural Vitamin A derivative ( &gt; = 10,000 per day ) . 7 . Patients take antioxidant Vitamin C E .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
</DOC>